The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to receive orforglipron or placebo
Compression/entrapment: Mechanical focal demyelination then axon loss at anatomical tunnels (carpal tunnel, cubital tunnel, tarsal tunnel, fibular head)
Using it after this date is risky, as it may have lost potency or become contaminated
To help avoid bruising, don't rub the area
In a study involving patients with DM2 who were not responding adequately to metformin, lixisenatide demonstrated the most effective efficacy-to-tolerance ratio at a dose of 20 g administered once daily
Rs 320 / VialGet Latest Price Recombinant Human Erythropoietin (rHuEPO) 4000 IU injection is an erythropoiesis-stimulating agent (ESA) used to treat anemia resulting from specific medical conditions